Screener
Arcus Biosciences RCUS Income Tax
Income Tax at other companies
Other financials
Where this comes from
Reported directly by Arcus Biosciences in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The source filing: Arcus Biosciences’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001724521-26-000044
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Interest expense | (3) | (2) | (6) | (3) |
| Total non-operating income, net | 5 | 8 | 11 | 18 |
| Income (loss) before income taxes | (91) | — | (219) | (112) |
| Income tax expense | — | — | — | — |
| Net income (loss) | $(91) | — | $(219) | $(112) |
| Net income (loss) per share: | ||||
| Basic | $(0.72) | — | $(1.74) | $(1.09) |
| Diluted | $(0.72) | — | $(1.74) | $(1.09) |
Item 1. Financial Statements
FAQ
- What is Arcus Biosciences's income tax?
- Arcus Biosciences (RCUS) reported income tax of $0 in Q2 2026.
- What is the long-term trend for Arcus Biosciences's income tax?
- Over 4 years (2021 to 2025), Arcus Biosciences's income tax has grown at a -100.0% compound annual growth rate (CAGR), from $2M to $0.
- What does income tax mean?
- Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.
Ask your AI about Arcus Biosciences's income tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude